Episode Details

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company receiving the first tranche of a €4 million non-dilutive grant from Wallonia and what it means for the advancement of its GF-1002 MASH programme. Leire confirmed that the initial instalment has now been received, calling it a “landmark moment” for the company. He emphasised that the funding provides “a significant boost to our cash runway with zero equity cost to investors,” allowing Genflow to focus fully on advancing its science without dilution to shareholders. The grant directly supports the company’s MASH programme, targeting advanced metabolic dysfunction-associated steatohepatitis, which Leire described as one of the most significant unmet medical needs of this generation. He noted that in advanced stages of the disease, “there is simply no treatment option other than liver transplant,” positioning the company’s gene therapy approach as a potential solution to a serious clinical gap. Beyond MASH, Leire outlined additional pipeline opportunities, including glaucoma, sarcopenia and the ongoing dog study, where positive interim results have already been announced. Final results from the dog study and biological age data could potentially support a trade sale to an animal health company. In ophthalmology, a six-month glaucoma proof-of-concept study is expected to begin soon, targeting retinal ganglion cell regeneration rather than solely reducing ocular pressure. For more interviews like this, visit Proactive's YouTube channel, give this video a like, subscribe to the channel and enable notifications so you don’t miss future updates. #GenflowBiosciences #DrEricLeire #MASH #GeneTherapy #BiotechNews #WalloniaGrant #NonDilutiveFunding #GlaucomaResearch #Sarcopenia #AnimalHealth #BiotechInvesting #HealthcareInnovation #ProactiveInvestors